

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-10 (Cancelled).

11. (Currently Amended) A method of promoting the healing of a wound, or fibrotic disorder, with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:

- i) human IL-10, and
- ii) a partially modified form of human IL-10, ~~or a fragment thereof, that~~ differs from human IL-10 by the addition, deletion or substitution of at least one amino acid and that has at least 95% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10, sufficient to effect said promotion with reduced scarring.

12. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

13. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.

14. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.

15. (Previously Presented) The method according to claim 11, wherein the agent is administered to a wound site or site of a fibrotic disorder.

16. (Previously Presented) The method according to claim 11, wherein the agent is administered at a concentration of between about  $1\mu\text{M}$  and about  $10\mu\text{M}$ .

17. (Previously Presented) The method according to claim 16, wherein the agent is administered at a concentration of between about  $2.5\mu\text{M}$  and about  $5\mu\text{M}$ .

18. and 19. (Cancelled).